SystImmune and parent company Sichuan Biokin Pharmaceutical have received regulatory approval in China for iza-bren, als...
As cannabis use expands globally and regulatory frameworks continue to evolve, healthcare systems are increasingly confr...
The search for safer and more effective pain therapies remains one of medicine's most pressing challenges. Despite advan...
The COVID-19 pandemic demonstrated that scientific discovery can move at extraordinary speed, but it also expose...
Artificial intelligence is rapidly transforming biologics discovery, but the industry's focus is shifting from generatin...
Despite decades of advances in oncology, many solid tumours remain difficult to treat effectively without exposing patie...
The RNA revolution is entering a new chapter. While mRNA transformed the industry's perception of nucleic acid therapeut...
Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused o...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
As biotechnology enters an increasingly data-driven era, organisations are rethinking how discovery, clinical developmen...
As biologics and cell and gene therapies continue to advance, manufacturing infrastructure is emerging as a critical det...
As cell and gene therapies move from clinical promise to commercial reality, the industry is increasingly recognising th...
At BIO International Convention 2026 in San Diego, BioSpectrum Asia spoke with Dr. Christoffer Norn, Co-founder and CEO ...
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced ...
Sonire Therapeutics has received approximately $13 million in non-dilutive funding through Japan’s NEDO Deep-Tech ...
WuXi Biologics’ Suzhou Biosafety Testing Center has passed a European Medicines Agency Good Manufacturing Practice...
MindWalk Holdings Corp. is positioning biological data infrastructure as a key bottleneck in AI-enabled drug discovery, ...
Minghui Pharmaceutical has presented complete Phase I/II clinical data for MHB018A, a subcutaneous anti-IGF-1R antibody ...
Lundbeck has presented preliminary Phase II Part A data for asedebart, an investigational anti-adrenocorticotropic hormo...
Rznomics has presented interim Phase 1/2a clinical data for RZ-001, its RNA editing-based anticancer gene therapy for re...
Inflammatory bowel disease is becoming a growing focus within immunology innovation across Asia-Pacific, as the region s...
As cell and gene therapies advance toward commercial reality, the industry's focus is rapidly shifting beyond manufactur...
Sanofi has received European Commission approval for subcutaneous Sarclisa, or isatuximab, in combination with standard-...
Argo Biopharma will present updated Phase II results for BW-20805, its investigational siRNA therapy for hereditary angi...
Otsuka has reported positive interim Phase III VISIONARY data showing that VOYXACT preserved kidney function over 12 mon...
